COVID-19 PandemicPhase 2COVID-19NCT05239832
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Phase 2 study testing Recombinant SARS-CoV-2 Fusion Protein Vaccine in people with COVID-19 Pandemic, run by Livzon Pharmaceutical Group Inc. at 1 site in China.
Trial summary
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19 Pandemic
- What is being tested?
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteChina
- Study dates
- 5 Aug 2021to 5 Aug 2022
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy participants aged 18 years and older who have completed the second dose of 2-dose regimen of SARS-CoV-2 vaccine (Vero cell) Inactivated in the past 3 months;
- Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
- In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
- Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.
Who cannot join
- 1. Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR. 2. History of previous SARS infection. 3. Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.
- 4. History of severe allergy to any vaccine or any ingredient of the vaccine including aluminum adjuvant, e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), dyspnea, angioedema, etc..
- 5. People who currently suffer from the following diseases:
- Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
- Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
- Patients with congenital or acquired angioedema/neuroedema;
Show all 13Show fewer
- A history of congenital or acquired immunodeficiency or autoimmune disease (except for mild psoriasis, controllable autoimmune thyroid disease, vitiligo, or stable celiac disease that does not require immunosuppressive or immunomodulatory therapy); no spleen , or history of spleen surgery, history of trauma, or treatment with immunomodulators within 6 months, such as: glucocorticoid with the dose causing immunosuppressive (dose reference: equivalent to prednisone 20mg/day, more than one week); or monoclonal antibody ; or thymosin; or interferon, etc.; but local medication (such as ointment, eye drops, inhalation or nasal spray) is allowed.
- Patients with active tuberculosis, viral hepatitis, human immunodeficiency virus or syphilis infection.
- Patients with acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases: history of chronic respiratory diseases (including moderate to severe asthma, COPD, pulmonary fibrosis), hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmHg) And/or diastolic blood pressure ≥100mmHg), history of severe cardiovascular disease (including heart failure, coronary artery disease, cardiomyopathy), history of chronic kidney disease, history of cancer (except for basal cell carcinoma), diabetes (unsatisfied blood sugar control or diabetes related serious complications).
- 6. Received attenuated live vaccine within 28 days before the vaccination or any subunit vaccines and inactivated vaccines within 14 days before the vaccination.
- 7. Injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; or with the plan to use such product within 6 month after immunization.
- 8. Pregnant (including positive urine pregnancy test for women of childbearing age) or breastfeeding women. Or women or their partners who have a pregnancy plan within 3 months after the trial vaccination.
- 9. Have participated in or are participating in other COVID-19 related clinical trials, or are participating in other drug clinical trials; 10. Those considered by the investigator as inappropriate to participate in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Read the detailed description
This is a single arm, open-label clinical study. 34 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines will be enrolled in this study to evaluate the safety and immunogenicity of V-01.
The participants will be collected blood before immunization, on day 7, day 14, day 28, day 90 and 6 month to evaluate humoral immunity.
All adverse events (AEs) within 30 minutes and 0-7 days after booster immunization, and unsolicited AEs from 8 to 28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization will be collected from all participants.
- Conditions
- COVID-19 Pandemic
- Being tested
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Recombinant SARS-CoV-2 Fusion Protein VaccineBiological
Also called V-01
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
| Study group | Role | What they receive |
|---|---|---|
| V-01 COVID-19 Vaccine | Experimental | 10 μg(0.5ml)/vial, one dose administrated by intramuscular injection Receives: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events (AEs)
The incidence of adverse events (AEs) occured within 30 minutes, 0-7 days, 0-30 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization.
Measured: Within 12 months after booster immunization.
Geometric Mean Titer (GMT)
GMT of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization
Measured: 28 days after booster immunization
Geometric Mean Increase (GMI)
GMI of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization
Measured: 28 days after booster immunization
Seroconvension rate
Seroconvension rate of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization
Measured: 28 days after booster immunization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2022
- Study start5 Aug 2021
- Primary completion29 Sep 2021
- Study completion5 Aug 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 PandemicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Livzon Pharmaceutical Group Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05239832
- Sponsor's protocol ID
- V-01-Booster-01
- Acronym
- COVID-19
- Status last verified
- Feb 2022
- First submitted
- 10 Feb 2022
- Last updated
- 3 Mar 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
- ClinicalTrials.gov ID
- NCT05239832
- Acronym / sponsor ID
- COVID-19 / V-01-Booster-01
- Conditions
- COVID-19 Pandemic
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry (pharma, biotech, devices)
- Study start
- 5 Aug 2021 (actual)
- Primary completion
- 29 Sep 2021 (actual)
- Study completion
- 5 Aug 2022 (estimated)
- First posted
- 15 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Detailed description
This is a single arm, open-label clinical study. 34 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines will be enrolled in this study to evaluate the safety and immunogenicity of V-01.
The participants will be collected blood before immunization, on day 7, day 14, day 28, day 90 and 6 month to evaluate humoral immunity.
All adverse events (AEs) within 30 minutes and 0-7 days after booster immunization, and unsolicited AEs from 8 to 28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization will be collected from all participants.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| V-01 COVID-19 Vaccine | Experimental | Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine10 μg(0.5ml)/vial, one dose administrated by intramuscular injection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy participants aged 18 years and older who have completed the second dose of 2-dose regimen of SARS-CoV-2 vaccine (Vero cell) Inactivated in the past 3 months;
- Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
- In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
- Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.
Key exclusion criteria (13 listed)
- 1. Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR. 2. History of previous SARS infection. 3. Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.
- 4. History of severe allergy to any vaccine or any ingredient of the vaccine including aluminum adjuvant, e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), dyspnea, angioedema, etc..
- Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
- Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
- Patients with congenital or acquired angioedema/neuroedema;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Recombinant SARS-CoV-2 Fusion Protein VaccineAlso: V-01The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection. | Biological | V-01 COVID-19 Vaccine |
Primary outcome
Incidence of adverse events (AEs)
Time frame: Within 12 months after booster immunization.
The incidence of adverse events (AEs) occured within 30 minutes, 0-7 days, 0-30 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization.
Geometric Mean Titer (GMT)
Time frame: 28 days after booster immunization
GMT of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization
Geometric Mean Increase (GMI)
Time frame: 28 days after booster immunization
GMI of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization
Seroconvension rate
Time frame: 28 days after booster immunization
Seroconvension rate of SARS-CoV-2 neutralizing antibody on 14 days and 28 days after booster immunization
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2022.
Related trials for COVID-19 Pandemic
Active, not recruiting
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
Liver Diseases, Alcohol Use Disorder
Enrolling by invitationObservational study
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic
Dementia
Active, not recruitingPhase 2
Improving Mental Health Among the LGBTQ+ Community
Anxiety, Depression
Active, not recruitingObservational study
COMMUNITY - the COVID-19 Immunity Study
COVID 19, Respiratory Synctial Virus
RecruitingObservational study
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
COVID-19 Infection, Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Recombinant SARS-CoV-2 Fusion Protein Vaccine in people with COVID-19 Pandemic, run by Livzon Pharmaceutical Group Inc. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events (AEs) (time frame: Within 12 months after booster immunization.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2022.